Is NVAX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Sanofi partnership and milestones, with revenue (2026 guidance) at ~$230 million to $270 million range guided for full-year 2026. The bear case rests on novavax remains a speculative small-cap biotech with meaningful risks. Analysts covering it are spread from $7.00 to $25.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Novavax remains a speculative small-cap biotech with meaningful risks. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $7.00, -4.0% from the $7.29 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Sanofi partnership and milestones. The Sanofi relationship is the anchor of the new Novavax. The most optimistic analyst target on NVAX is $25.00, +242.9% from the $7.29 price. That figure is only reachable if this thesis works close to its best case.

Novavax remains a speculative small-cap biotech with meaningful risks. Its revenue increasingly depends on partners such as Sanofi and Pfizer, so milestone timing, partner decisions, and program prioritization are largely outside its control. Demand for COVID vaccines has fallen sharply from pandemic peaks, and seasonal booster uptake is uncertain, which pressures the underlying Nuvaxovid franchise. The company has a history of cash burn, dilution, manufacturing setbacks, and volatile results, and its stock can swing sharply on trial data, regulatory news, and deal announcements. Guidance ranges are wide and depend on licensing income that may not recur. Competition in vaccines and adjuvants is intense, and there is no guarantee that new Matrix-M partnerships will materialize on favorable terms. The most pessimistic published target is $7.00, -4.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Novavax is a biotechnology company known for protein-based vaccines and its proprietary Matrix-M adjuvant, a saponin-based compound that boosts the immune response to a vaccine.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Sanofi partnership and milestones) stalling in the reported numbers rather than in the narrative, the risk above (novavax remains a speculative small-cap biotech with meaningful risks) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is that the pivot to a partnership-and-royalty model with Sanofi and Pfizer could turn Matrix-M and Nuvaxovid into steady milestone and royalty income at lower cost. The bear case is that Novavax is a small, volatile biotech whose revenue is lumpy and dependent on partners, with falling COVID vaccine demand and a history of cash burn and dilution. Weigh both against your portfolio.

Novavax develops protein-based vaccines and owns the Matrix-M adjuvant, a compound that strengthens the immune response to a vaccine. Its main product is Nuvaxovid, a protein-based COVID-19 vaccine. By 2026 it has shifted toward commercializing products through partners and licensing Matrix-M to companies like Pfizer, earning upfront payments, milestones, and royalties rather than relying only on direct sales.

Under the partnership, Sanofi took on much of the commercialization of Nuvaxovid and gained rights to use Matrix-M in its own vaccines. In exchange, Novavax became eligible for large additional milestone payments, including amounts tied to Nuvaxovid and a COVID-influenza combination program, plus potential royalties. It is the anchor of Novavax's shift to a lighter, partner-driven business model.